Forthcoming prognostic markers for esophageal cancer: A systematic review and meta-analysis

Journal of Gastrointestinal Oncology

Volumn 5, Issue 1, 2014, Pages 67-76

  Nagaraja, Vinayak ^a   Eslick, Guy D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Esophageal cancer; Insulin like growth factor axis (IGF axis); MET or MNNG HOS Transforming gene (c Met); Octamer binding transcription factor 4 (OCT4); Oestrogen receptors (ER); Sex determining region Y box 2 (SOX2)

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; OCTAMER TRANSCRIPTION FACTOR 4; PROGESTERONE RECEPTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER;

ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

EID: 84995772010     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.054     Document Type: Article

References (97)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
3. Thompson SK, Ruszkiewicz AR, Jamieson GG, et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol 2008;15:3447-58.
4. Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1126-34.
5. Xu XL, Ling ZQ, Chen SZ, et al. The impact of E-cadherin expression on the prognosis of esophageal cancer: a metaanalysis. Dis Esophagus 2014;27:79-86.
6. Li L, Zhao J, Wu Z, et al. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther 2009;30:589-96.
7. Li C, Li Z, Zhu M, et al. Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a metaanalysis. PLoS One 2012;7:e44764.
8. Yu WW, Guo YM, Zhu M, et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepatogastroenterology 2011;58:426-31.
9. Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal Cancer. J Gastrointest Surg 2012;16:1821-9.
10. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
11. Donohoe CL, Pidgeon GP, Lysaght J, et al. Obesity and gastrointestinal cancer. Br J Surg 2010;97:628-42.
12. Pollak MN, Schernhammer ES, Hankinson SE. Insulinlike growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
13. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
14. Comoglio PM, Giordano S, Trusolino L. Drug development of Met inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
15. Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol 2009;36:S52-8.
16. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
17. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22.
18. Zou HY, Li Q, Lee JH, et al. An orally available smallmolecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17.
19. Gubbay J, Collignon J, Koopman P, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346:245-50.
20. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev 1997;7:338-44.
21. Sinclair AH, Berta P, Palmer MS, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240-4.
22. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999;27:1409-20.
23. Ferrari S, Harley VR, Pontiggia A, et al. SRY, like HMG1, recognizes sharp angles in DNA. EMBO J 1992;11:4497-506.
24. Weiss MA. Floppy SOX: mutual induced fit in hmg (highmobility group) box-DNA recognition. Mol Endocrinol 2001;15:353-62.
25. Gen Y, Yasui K, Zen Y, et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2010;202:82-93.
26. Schöler HR, Ruppert S, Suzuki N, et al. New type of POU domain in germ line-specific protein Oct-4. Nature 1990;344:435-9.
27. Schöler HR. Octamania: the POU factors in murine development. Trends Genet 1991;7:323-9.
28. Pesce M, Schöler HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 2001;19:271-8.
29. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9.
30. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer 2002;102:271-4.
31. Wang LY. Estrogen and progesterone receptors in esophageal carcinoma cells. Zhonghua Zhong Liu Za Zhi 1991;13:23-5.
32. Utsumi Y, Nakamura T, Nagasue N, et al. Role of estrogen receptors in the growth of human esophageal carcinoma. Cancer 1989;64:88-93.
33. Nozoe T, Oyama T, Takenoyama M, et al. Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res 2007;13:4046-50.
34. Moher D, Liberati A, TetzlaffJ, et al. Preferred reporting items for systematic reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
35. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
36. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
37. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
38. Orwin R. A fail-safe N for effect size in meta-analysis. Journal of educational statistics 1983;8:157-9.
39. Li C, Yan Y, Ji W, et al. OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One 2012;7:e49693.
40. Wang Q, He W, Lu C, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009;29:1233-41.
41. Akin I, Kische S, Paranskaya L, et al. Predictive factors for pacemaker requirement after transcatheter aortic valve implantation. BMC Cardiovasc Disord 2012;12:87.
42. Zhou X, Huang GR, Hu P. Over-expression of Oct4 in human esophageal squamous cell carcinoma. Mol Cells 2011;32:39-45.
43. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42.
44. Bahl K, Saraya A, Sharma R. Increased levels of circulating and tissue mRNAs of Oct-4, Sox-2, Bmi-1 and nanog is ESCC patients: potential Tool for minimally invasive cancer diagnosis. Biomark Insights 2012;7:27-37.
45. Saigusa S, Mohri Y, Ohi M, et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep 2011;26:1069-74.
46. Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol 2009;40:1768-73.
47. Liu L, Chirala M, Younes M. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res 2004;24:2919-24.
48. Wang QM, Qi YJ, Jiang Q, et al. Relevance of serum estradiol and estrogen receptor beta expression from a high-incidence area for esophageal squamous cell carcinoma in China. Med Oncol 2011;28:188-93.
49. Kalayarasan R, Ananthakrishnan N, Kate V, et al. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus 2008;21:298-303.
50. Zuguchi M, Miki Y, Onodera Y, et al. Estrogen receptor a and ß in esophageal squamous cell carcinoma. Cancer Sci 2012;103:1348-55.
51. Saeki H, Oda S, Kawaguchi H, et al. Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 2002;98:8-13.
52. Tuynman JB, Lagarde SM, Ten Kate FJ, et al. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-8.
53. Houldsworth J, Cordon-Cardo C, Ladanyi M, et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22.
54. Porte H, Triboulet JP, Kotelevets L, et al. Overexpression of stromelysin-3, BM-40/SPARC, and Met genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998;4:1375-82.
55. Anderson MR, Harrison R, Atherfold PA, et al. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res 2006;12:5936-43.
56. Lennerz JK, Kwak EL, Ackerman A, et al. Met amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-10.
57. Kato H, Arao T, Matsumoto K, et al. Gene amplification of EGFR, HER2, FGFR2 and Met in esophageal squamous cell carcinoma. Int J Oncol 2013;42:1151-8.
58. Imsumran A, Adachi Y, Yamamoto H, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 2007;28:947-56.
59. Donohoe CL, Doyle SL, Mcgarrigle S, et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg 2012;99:387-96.
60. Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol 2012;107:196-204.
61. Kalinina T, Bockhorn M, KaifiJT, et al. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010;127:1931-40.
62. Iravani S, Zhang HQ, Yuan ZQ, et al. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 2003;34:975-82.
63. Zhao R, Macdonald K, Casson AG. Insulin-like growth factor type I receptor gene expression and obesity in esophageal adenocarcinoma. Mol Carcinog 2009;48:982-8.
64. Lin YC, Wu MY, Li DR, et al. Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. World J Gastroenterol 2004;10:3235-9.
65. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
66. He W, Li K, Wang F, et al. Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. World J Gastroenterol 2012;18:712-9.
67. Gen Y, Yasui K, Nishikawa T, et al. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci 2013;104:810-6.
68. Russo J, Russo IH. Breast development, hormones and cancer. Adv Exp Med Biol 2008;630:52-6.
69. Chen JQ, Brown TR, Yager JD. Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv Exp Med Biol 2008;630:1-18.
70. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010;66:33-8.
71. Sharpe RM. The roles of oestrogen in the male. Trends Endocrinol Metab 1998;9:371-7.
72. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
73. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985;77:209-23.
74. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A 1986;83:6489-93.
75. Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59.
76. Sanders DS, Bruton R, Darnton SJ, et al. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int J Cancer 1998;79:573-9.
77. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting betacatenin signaling in an adhesion-independent manner. J Cell Biol 2001;153:1049-60.
78. Stockinger A, Eger A, Wolf J, et al. E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J Cell Biol 2001;154:1185-96.
79. Stewart DB, Nelson WJ. Identification of four distinct pools of catenins in mammalian cells and transformationdependent changes in catenin distributions among these pools. J Biol Chem 1997;272:29652-62.
80. Barker N, Morin PJ, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000;77:1-24.
81. Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett's esophagusdysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-44.
82. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
83. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasiadysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
84. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-11.
85. Davies G, Jiang WG, Mason MD. Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion. Anticancer Res 1999;19:547-52.
86. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71.
87. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005;7:75-84.
88. Lukanova A, Söderberg S, Stattin P, et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 2002;13:509-16.
89. Sell C, Rubini M, Rubin R, et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-21.
90. Hellawell GO, Turner GD, Davies DR, et al. Expression of the type 1 insulin-like growth factor receptor is upregulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
91. Law JH, Habibi G, Hu K, et al. Phosphorylated insulinlike growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46.
92. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23-37.
93. Samani AA, Yakar S, Leroith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
94. Howard JM, Beddy P, Ennis D, et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010;97:1020-7.
95. Piao W, Wang Y, Adachi Y, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008;7:1483-93.
96. Liu YC, Leu CM, Wong FH, et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002;9:665-74.
97. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.